Chongqing Precision Biotech Co., Ltd Drug Pipeline

Chongqing Precision Biotech Co., Ltd. maintains an active clinical portfolio of over 30 trials, with 32 total trials registered since 2008. The company's pipeline is heavily weighted toward early-stage development, consisting primarily of Phase 1 and Phase 2 trials; specifically, 30 active programs are in Phase 1, and 6 are in Phase 2. Chongqing Precision Biotech focuses its clinical development efforts on two therapeutic areas, with a significant concentration in oncology. Within oncology, which represents 181% of active programs, the company is pursuing multiple indications, including Lung Cancer (General), with 9 active trials, Solid Tumor (Advanced), with 7 active trials, and Gastric Cancer and Colorectal Cancer, each with 5 active trials. The company also has 4 active trials in ALL (Acute Lymphoblastic Leukemia). A smaller number of trials are dedicated to immunology. The absence of Phase 3 or Phase 4 trials suggests a focus on early-stage clinical research.